Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Tocagen Inc. Stories

2014-04-10 08:29:39

Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ -- Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco. High grade gliomas include...

2014-03-25 08:29:38

Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization SAN DIEGO, March 25, 2014 /PRNewswire/ -- Tocagen Inc. today announced that Jamey Skillings, M.D., has been named Senior Vice President and Chief Medical Officer. Dr. Skillings joins Tocagen from Pfizer, where she was most recently vice president of global medical affairs for oncology. Dr. Skillings' clinical leadership at prior pharmaceutical companies led to several oncology...

2014-03-11 08:29:44

Intravenous Delivery Is An Important Advancement in the Development of Toca 511, Creates Opportunity For Use In Additional Cancer Indications SAN DIEGO, March 11, 2014 /PRNewswire/ -- Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG), the most...

2013-11-26 08:27:27

Additional Preclinical Studies Demonstrate Potential for Intravenous Administration of Toca 511 and Use in Combination with Temozolomide and Radiation SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Tocagen Inc. today announced that interim clinical data from two ongoing Phase I investigational studies presented at the Society for Neuro-Oncology (SNO) Annual Meeting in San Francisco showed that Toca 511 administration followed by courses of oral Toca FC was safe and well tolerated in 60...

2013-11-22 08:23:09

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Tocagen Inc. today announced that six presentations on Toca 511 will be given at the Society of Neuro-Oncology (SNO) Annual Meeting, including interim clinical data from two ongoing Phase I investigational studies, which show that, to date, Toca 511 administration followed by oral courses of Toca FC is safe and well tolerated, and demonstrated antitumor activity in some patients with high grade glioma (HGG). HGG includes glioblastoma multiforme (GBM),...

2013-07-02 23:18:27

Study investigated treatment for canine brain tumors while aiding development of potential new therapy for humans. Chicago, IL (PRWEB) July 02, 2013 The American Brain Tumor Association (ABTA) today announced highlights from the final report on a grant supporting clinical research of naturally-occurring canine brain tumors to discover more effective methods of treatment for human brain tumors. The $200,000 grant was awarded by the ABTA in 2011 to San Diego-based Tocagen, Inc. for the...

2013-06-19 08:30:22

NEW YORK, June 19, 2013 /PRNewswire/ -- Voices Against Brain Cancer (VABC), a not-for-profit organization dedicated to finding a cure for brain cancer, today announced that it has awarded Tocagen Inc. (www.tocagen.com) a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4). Tocagen is a privately held biopharmaceutical company developing novel treatments for advanced cancer, with an...

2013-05-30 12:28:06

First Combination of ClearPoint(®) Neuro Intervention System within VISIUS(®) Surgical Theatre to Achieve Real-Time MRI-Guided Delivery of Investigational Gene Therapy Drug Toca 511 Highlights Collaboration among Three High-Tech Healthcare Companies to Deliver Novel Therapy IRVINE, CA, May 30, 2013 /PRNewswire/ - MRI Interventions, Inc. (OTCQB:MRIC) and IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS") today announced that a surgical team at a leading U.S. neuroscience institution...

2012-02-07 10:33:00

RESEARCH TRIANGLE PARK, N.C., SAN DIEGO and TARRYTOWN, N.Y., Feb. 7, 2012 /PRNewswire/ -- Siemens Healthcare Diagnostics announces two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen -- marking a major step for Siemens (NYSE: SI) into this important and fast-growing segment of the in vitro diagnostics (IVD) market. Both partnerships intend to leverage the clinical trial and commercialization options within Siemens' CLIA laboratory, as well as...

2012-02-03 19:00:09

Study conducted in mice treated with Toca 511 and 5-FC Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma. Almost all mice receiving the top dose of Toca 511 followed by 5-FC were still alive at 180 days, which was the termination date for the experiment, whereas all control mice died by day 43. The article was published...